Trial Profile
Phase II Study of Neoadjuvant Nab-paclitaxel (PTX) and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 14 Dec 2019 Results assessing safety and activity of albumin-bound paclitaxel plus trastuzumab in breast cancer patients, presented at the 42nd Annual San Antonio Breast Cancer Symposium.
- 26 Aug 2019 Status changed from completed to discontinued.
- 08 May 2019 Status changed to completed according to University Hospital Medical Information Network - Japan record.